BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement
BioNxt Solutions has successfully closed the first tranche of its non-brokered private placement, raising $1.6 million through convertible debenture units. Each unit comprises a $0.50 principal amount of 8.0% unsecured convertible debentures and one common share purchase warrant.
The debentures feature an 8.0% annual interest rate, payable at maturity in two years, and are convertible to common shares at $0.50 per share. Warrants are exercisable at $0.60 per share until February 28, 2027.
As part of the offering, the company paid $128,000 in cash fees and issued 256,000 finder warrants to Canaccord Genuity Corp. The proceeds will fund product development, commercialization, intellectual property filings, debt repayment, and working capital.
BioNxt Solutions ha concluso con successo la prima tranche del suo collocamento privato non intermediato, raccogliendo 1,6 milioni di dollari attraverso unità di obbligazioni convertibili. Ogni unità comprende un importo principale di $0,50 di obbligazioni convertibili non garantite con un tasso di interesse dell'8,0% e un warrant per l'acquisto di azioni ordinarie.
Le obbligazioni presentano un tasso di interesse annuo dell'8,0%, pagabile a scadenza tra due anni, e sono convertibili in azioni ordinarie a $0,50 per azione. I warrant sono esercitabili a $0,60 per azione fino al 28 febbraio 2027.
Come parte dell'offerta, la società ha pagato 128.000 dollari in commissioni in contante e ha emesso 256.000 warrant per trovatori a Canaccord Genuity Corp. I proventi finanzieranno lo sviluppo del prodotto, la commercializzazione, le registrazioni di proprietà intellettuale, il rimborso del debito e il capitale circolante.
BioNxt Solutions ha cerrado con éxito la primera tranche de su colocación privada no intermediada, recaudando 1.6 millones de dólares a través de unidades de bonos convertibles. Cada unidad comprende un monto principal de $0.50 en bonos convertibles no asegurados con un interés del 8.0% y una opción de compra de acciones ordinarias.
Los bonos tienen una tasa de interés anual del 8.0%, pagadera al vencimiento en dos años, y son convertibles en acciones ordinarias a $0.50 por acción. Las opciones son ejercitables a $0.60 por acción hasta el 28 de febrero de 2027.
Como parte de la oferta, la compañía pagó 128,000 dólares en comisiones en efectivo y emitió 256,000 opciones para buscadores a Canaccord Genuity Corp. Los ingresos financiarán el desarrollo de productos, la comercialización, los registros de propiedad intelectual, el pago de deudas y el capital de trabajo.
BioNxt Solutions는 비중개 사모 배치의 첫 번째 분할을 성공적으로 마감하고 160만 달러를 전환사채 단위를 통해 모금했습니다. 각 단위는 8.0%의 무담보 전환사채의 원금 $0.50와 하나의 보통주 매수권을 포함합니다.
전환사채는 연 8.0%의 이자율을 특징으로 하며, 만기 시 2년 후에 지급되며, 주당 $0.50에 보통주로 전환할 수 있습니다. 매수권은 2027년 2월 28일까지 주당 $0.60에 행사할 수 있습니다.
이번 공모의 일환으로 회사는 Canaccord Genuity Corp.에 128,000달러의 현금 수수료를 지급하고 256,000개의 발굴자 매수권을 발행했습니다. 이 자금은 제품 개발, 상용화, 지적 재산권 등록, 부채 상환 및 운영 자본에 사용될 것입니다.
BioNxt Solutions a réussi à clôturer la première tranche de son placement privé non intermédié, levant 1,6 million de dollars grâce à des unités d'obligations convertibles. Chaque unité se compose d'un montant principal de 0,50 $ d'obligations convertibles non sécurisées à 8,0 % et d'un bon de souscription d'actions ordinaires.
Les obligations présentent un taux d'intérêt annuel de 8,0 %, payable à l'échéance dans deux ans, et sont convertibles en actions ordinaires à 0,50 $ par action. Les bons de souscription sont exerçables à 0,60 $ par action jusqu'au 28 février 2027.
Dans le cadre de l'offre, la société a payé 128 000 dollars en frais en espèces et a émis 256 000 bons de souscription à Canaccord Genuity Corp. Les produits serviront à financer le développement de produits, la commercialisation, les dépôts de propriété intellectuelle, le remboursement de dettes et le fonds de roulement.
BioNxt Solutions hat erfolgreich die erste Tranche seiner nicht vermittelten Privatplatzierung abgeschlossen und 1,6 Millionen Dollar durch wandelbare Schuldverschreibungen gesammelt. Jede Einheit besteht aus einem Nennbetrag von 0,50 $ von 8,0 % unbesicherten wandelbaren Schuldverschreibungen und einem Bezugsrecht auf Stammaktien.
Die Schuldverschreibungen haben einen jährlichen Zinssatz von 8,0 %, der bei Fälligkeit in zwei Jahren zahlbar ist, und sind zu einem Preis von 0,50 $ pro Aktie in Stammaktien umwandelbar. Die Bezugsrechte können bis zum 28. Februar 2027 zu 0,60 $ pro Aktie ausgeübt werden.
Im Rahmen des Angebots zahlte das Unternehmen 128.000 Dollar an Barprovisionen und gab 256.000 Finder-Warrants an Canaccord Genuity Corp. aus. Die Einnahmen werden zur Finanzierung der Produktentwicklung, der Kommerzialisierung, der Einreichung von geistigem Eigentum, der Schuldenrückzahlung und des Betriebskapitals verwendet.
- Secured $1.6M in new funding
- Debt repayment included in use of proceeds
- Strategic investment in product development and commercialization
- 8% interest rate on debentures indicates higher cost of capital
- Potential dilution from convertible debentures and warrants
- Additional finder's fees and warrants increase total cost of financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
VANCOUVER, BC / ACCESS Newswire / February 28, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:4XT), is pleased to announce today that it has closed the first tranche of its previously announced non‐brokered private placement (the "Offering") of convertible debenture units ("Debenture Units") for gross proceeds of
The Debentures bear interest from their issue date at
Each Warrant is exercisable to acquire one Common Share (a "Warrant Share") at an exercise price of
In connection with the Offering, the Company paid a cash fee of
The Debentures and the Warrants comprising each Debenture Unit, the Finder's Warrants and any Common Shares issuable upon conversion or exercise thereof, are subject to a statutory four month and one day hold period until June 29, 2025.
The Company intends to use the net proceeds from the Offering for product development and commercialization, intellectual property filings, debt repayment, and general working capital.
This news release does not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Debentures and the Shares which may be issued on exercise thereof have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co‐Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt‐solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward‐Looking" Information
This news release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking information in this news release includes the intention to close one or more tranches of the Offering in the future and the anticipated use of the proceeds from the Offering. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
FAQ
What are the key terms of BNXTF's February 2025 convertible debenture offering?
How will BioNxt (BNXTF) use the proceeds from the February 2025 private placement?
What is the maturity period for BNXTF's February 2025 convertible debentures?
What fees did BNXTF pay for the February 2025 private placement?
